Scientists have created a vaccine that helps the body resist gaining fat. This new weekly injection works by reducing harmful ...

The mother, who resides in Campbell Hall, says his two older siblings had documented, severe reactions to the vaccine – ...

Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer at the JPMorgan Healthcare Conference to talk recent ...

Biotech has lagged even more. The S&P Biotechnology Select Industry Index has returned about 3 per cent annually over 10 ...

The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over ...

Vanguard hasn’t been immune to investors ... as it believes there is long-term potential with its vaccine development. While the strategy is overweight biotech, its limited exposure to ...

the Vanguard Group’s foundation, and Schwab Charitable. Most of this money is spent on legal fees paid to the firm of Siri & Glimstad. On the issue of polio vaccines, according to the Centers ...

The Vanguard Russell 2000 ETF tracks the performance ... Vaxcyte, on the other hand, is a California-based developer of vaccines, and Applied Industrial Technologies is a distributor of bearings ...

Merck just rewarded its shareholders again with a dividend hike. This Dow stock has come with a quarterly dividend for almost ...

Equities researchers at William Blair raised their FY2024 EPS estimates for shares of Moderna in a research report issued to ...

StockNews.com upgraded shares of Emergent BioSolutions (NYSE:EBS – Free Report) from a hold rating to a buy rating in a report released on Tuesday morning. EBS has been the topic of several other ...